Scope: Nutrigenomics is a rapidly expanding field that elucidates the link between diet-genome interactions. Recent evidence demonstrates that regulation of the epigenome, and in particular inhibition of histone deacetylases (HDACs), impact pathogenetic mechanisms involved in chronic disease. Few studies, to date, have screened libraries of bioactive compounds that act as epigenetic modifiers. This study screened a library of 131 natural compounds to determine bioactive compounds that inhibit Zn-dependent HDAC activity. Methods and results: Using class-specific HDAC substrates, we screened 131 natural compounds for HDAC activity in bovine cardiac tissue. From this screen, we identified 18 bioactive compound HDAC inhibitors. Using our class-specific HDAC substrates, we next screened these 18 bioactive compounds against recombinant HDAC proteins. Consistent with inhibition of HDAC activity, these compounds were capable of inhibiting activity of individual HDAC isoforms. Lastly, we report that treatment of H9c2 cardiac myoblasts with bioactive HDAC inhibitors was sufficient to increase lysine acetylation as assessed via immunoblot. Conclusion: This study provided the first step in identifying multiple bioactive compound HDAC inhibitors. Taken together, this report sets the stage for future exploration of these bioactive compounds as epigenetic regulators to potentially ameliorate chronic disease.
Introduction
Nutritional genomics, or nutrigenomics, is a rapidly emerging field that explores the link between diet-gene interactions [1] . Epigenetics is defined by heritable changes in gene expression that does not involve alterations in DNA sequence. Dynamic changes in the nucleosomal landscape, in part, via posttranslational modification (PTM) of histone tails play a central role in regulating DNA accessibility and thus gene transcription [2] . Diet can greatly impact the epigenetic landscape by regulating PTMs; therefore, epigenetics has emerged as a topic of interest in the field of nutrigenomics. Accumulating evidence has shown that dietary bioactive food components affect epigenetic marks and that these alterations impact pathogenetic mechanisms involved in heart disease [1, 3, 4] .
Histone acetylation provides a critical mechanism for epigenetic control of gene expression [5] . Histone acetyltransferases (HATs) and histone deacetylases (HDACs) govern the addition or removal of acetyl groups to lysine residues. Historically, HDACs have been studied in the context of chromatin, where they deacetylate histones and alter electrostatic properties of chromatin in a manner that favors gene repression [5] . Eighteen HDACs are encoded by distinct genes and grouped into four classes: class I (HDACs 1, 2, 3, and 8), class IIa (HDACs 4, 5, 7, and 9), class IIb (HDACs 6 and 10), and class IV (HDAC 11) HDACs require zinc for catalysis, (2 of 11) 1600744 whereas class III HDACs (SirT1-7), also known as sirtuins, require nicotinamide adenine dinucleotide (NAD + ) for catalytic activity [6] (Fig. 1) .
HDAC inhibitors have been shown to block cardiac hypertrophy, fibrosis, and inflammation in animal models of myocardial infarction, transverse aortic constriction, and hypertension [7] [8] [9] . More specifically, these beneficial effects on cardiac structure and function have been attributed to inhibition of Zn-dependent HDACs [10, 11] . Recent reports highlight diet and dietary bioactive compounds as regulators of HDAC activity and cardiac health [1, 3] . Most of these studies have typically focused on a single bioactive food compound in the regulation of disease. These studies have provided crucial insight into the importance for diet in regulation of epigenetic marks critical for the control of gene expression. Given the widespread implications for diet in the regulation of the epigenome, we screened a library of bioactive compounds against Zn-dependent HDAC activity. In this report, we screened a natural compound library, containing 131 bioactive compounds using an enzymatic HDAC assay previously established [12] that enables quantitative examination of classes I, IIa, and IIb Zn-dependent HDAC activity in tissue or cell homogenates. We selected a predesigned natural product compound library from SelleckChem; this limited selection bias yet allowed for the screening of unidentified as well as previously identified HDAC inhibitors to further substantiate our results. Using this assay, we report that 18 of the 131 bioactive compounds screened dose-dependently inhibited HDAC activity and consistent with these findings increased lysine acetylation. This report marks a first step in identifying multiple dietary bioactive compounds that function as HDAC inhibitors to potentially ameliorate chronic diseases and in particular cardiac dysfunction.
Materials and methods

HDAC activity assays
Bovine heart tissue was procured from the University of Nevada, Wolf Pack Meats, with care and handling of all animals conducted and approved by the University of Nevada, Reno, Institutional Animal Care and Use Committee (#00676). HDAC activity assays were completed as previously described [12] . Each substrate is based on -N-acylated lysine, derivatized on the carboxyl group with amino methylcoumarin (AMC) [13] . Heart tissue lysate was prepared in PBS (pH 7.4) containing 0.5% Triton X-100, 300 mM NaCl, and protease/phosphatase inhibitor cocktail (Thermo Fisher) using a Bullet Blender homogenizer (Next Advance). Tissue was clarified by centrifugation prior to determination of protein concentration using a BCA Protein Assay Kit (Pierce). Tissue (30 g protein/well) was then diluted into PBS buffer for a total volume of 100 L/well in a 96-well plate. For concentration-response determination, tissue was dosed with increasing semi-log scale concentrations of dietary compounds (SelleckChem Natural Product Library; L1400) for 2 h. Class-specific HDAC substrates were added (5 L of 1 mM DMSO stock solutions), and plates returned to the 37ЊC incubator for 2 h. Developer/stop solution was added (50 L per well of PBS with 1.5% Triton X-100, 3 M Trichostatin A (TSA), and 0.75 mg/mL trypsin) and plates incubated at 37ЊC for 20 min. Subsequent to deacylation, trypsin is used to release AMC, resulting in increased fluorescence. AMC fluorescence was measured via BioTek Synergy plate reader, with excitation and emission filters of 360 and 460 nm, respectively. Background signals from buffer blanks were subtracted, and GraphPad Prism used to calculate IC 50 substrates are susceptible to trypsin cleavage, resulting in increased fluorescence. Deacetylase activity was measured via BioTek Synergy plate reader as described above and data quantified using GraphPad Prism.
Cells and cell culture
H9c2 cells (ATCC; CRL-1446) were cultured in DMEM supplemented with 10% fetal bovine serum. At 90% confluence, H9c2 cells were treated with emodin (2 h; SelleckChem; S2295), gossypol (2 h; SelleckChem; S2303), luteolin (2 h; SelleckChem; S2320), quercetin dihydrate (2 h; SelleckChem; S2347), TSA (2 h; Sigma T8552), or DMSO.
Immunoblotting
Cell monolayers were washed with ice-cold PBS and scraped into ice-cold lysis buffer containing PBS (pH 7.4), 0.5% Triton X-100, 300 mM NaCl, and protease/phosphatase inhibitor cocktail (Thermo Fisher). Cultured cells were sonicated prior to clarification by centrifugation. Protein concentrations were determined using a BCA Protein Assay Kit (Pierce). Proteins were resolved by SDS-PAGE, transferred to nitrocellulose membranes (Bio-Rad) and probed with antibodies for acetyllysine (Cell Signaling Technology; 9441), Acetyl-H3K9/14 (Cell Signaling Technology; 9677), Total H3 (Cell Signaling Technology; 4499). HRP-conjugated secondary antibodies (Southern Biotech) were used at a concentration of 1:2000. Proteins were detected using a SuperSignal West Pico chemiluminescence system (Thermo Scientific) and a ChemiDoc XRS+ imager (Bio-Rad). Densitometry was performed using Image J software and statistical analyses conducted via GraphPad Prism software.
Statistical analyses
Statistical analysis was completed by ANOVA followed by post hoc testing (Tukey's test was used for post hoc (4 of 11) 1600744 -, no inhibition.
[M], molar.
analysis unless otherwise noted) using GraphPad Prism software. Statistical significance (defined as p < 0.05) is reported as applicable.
Results
Catalytic activity of class-specific HDAC substrates
HDAC activity can be determined via fluorescent substrates that contain acetyl-lysine moieties [14] . These substrates become susceptible to trypsin cleavage upon HDAC deacetylation and thus release the 7-amino-4-methlcoumarin (AMC) fluorophore [15] . Moreover, these substrates can be used to measure recombinant or endogenous (i.e. tissue/cell lysate) HDAC activity. Class-specific substrates for classes I, IIa, and IIb ( Fig. 1 ) HDACs have previously been described [12, 13, 16] . To assess selectivity of these substrates in our model, we treated heart tissue (30 g) with well-established class-specific and pan-HDAC inhibitors; structures illustrated for TSA (pan-HDAC inhibitor), MGCD0103 (class I HDAC inhibitor), DPAH (class IIa HDAC inhibitor), and Tubastatin A (class IIb/HDAC6 inhibitor; Fig. 2 ). As shown ( Fig. 2A) , treatment with the pan-HDAC inhibitor TSA significantly decreased catalytic HDAC activity of all substrates. Further analysis demonstrated that MGCD only inhibited class I HDAC activity (Fig. 2B) , while DPAH only inhibited class IIa HDAC activity ( Fig. 2C ) and TubA only inhibited class IIb HDAC activity (Fig. 2D) ; confirming the class selectivity of these substrates.
Select bioactive food compounds alter catalytic HDAC activity in the heart
In these experiments, we postulated that bioactive food compounds act as epigenetic modifiers that can inhibit HDAC activity. Using the class-selective HDAC substrates as described above, we thus screened a natural product library (SelleckChem) containing 131 bioactive compounds against HDAC activity in bovine cardiac tissue. We observed dosedependent inhibition of 18 bioactive compounds from the library screen (Table 1) , whereas a majority of the compounds did not alter HDAC activity even at the highest doses used for these studies (Supporting Information Table 1 ). Many of the bioactive compounds act as pan-HDAC inhibitors and thus attenuated classes I, IIa, IIb HDAC activity (Table 1) . This is reflected in Fig. 3 , where we observed dose-dependent pan-HDAC inhibition of nonflavonoids ( Fig. 3A and B) , emodin and gossypol, and flavonoids ( Fig. 3C and D) , luteolin and quercetin dihydrate. We did note, however, substrate specificity for a few of the compounds; where for instance apigenin and palmatine only inhibit class I HDAC activity while hematoxylin targeted class IIb HDACs for inhibition (Table 1) . Nonflavonoid and flavonoid compound structures were illustrated in Fig. 3 for emodin, gossypol, luteolin, and quercetin dihydrate; provided as representative compound structures for dietary HDAC inhibitors (Fig. 3) . 
Bioactive food compounds selectively inhibit recombinant HDAC activity
Data above demonstrated that 18 out of 131 bioactive compounds suppressed HDAC activity, yet it is unclear which HDAC is being targeted for inhibition. Using our HDAC activity assay, we further screened the 18 bioactive compounds at a chosen dose of 50 M against all recombinant classes I and II HDACs. This dose was chosen as it closely reflected a dose at or above the determined IC 50 for most of the screened compounds (Table 1) ; this was to ensure an adequate inhibitor concentration. In keeping with our screening assay above, the bioactive compounds were found to potently inhibit recombinant HDAC activity and pan-HDAC inhibitors targeted most of the classes I, IIa, and IIb HDACs for inhibition (Table 2) . Similar to Fig. 3 , pan-HDAC inhibition by nonflavonoids ( Fig. 4A and B) and flavonoids ( Fig. 4C and D) was adequate in suppressing activity of most of the recombinant HDACs. We further noted that emodin was only one of six compounds capable of inhibiting HDAC6 activity and one of two compounds able to inhibit HDAC7 activity ( Fig. 4 and Table 2 ). Quercetin dihydrate was one of only two compounds to significantly inhibit HDAC4 activity. Lastly, we observed no inhibition by caffeic acid (50 M) on any of the recombinant HDACs screened. However, caffeic acid was the least potent inhibitor of HDAC activity as determined by dose-response curves, where IC 50 values were greater than 80 M (Table 1) .
Dietary HDAC inhibitors enhance lysine acetylation of rat cardiac myocytes
Experiments outlined above clearly demonstrate that 18 of 131 bioactive compounds inhibit HDAC activity. Thus, we would postulate that treatment of cells with these identified bioactive HDAC inhibitors would increase lysine acetylation in rat cardiac myocytes. To test this postulate, we treated H9c2 (6 of 11) 1600744 myocytes for 2 h with 50 M of our bioactive HDAC inhibitors shown above (Figs. 3 and 4) and examined lysine and histone acetylation of whole cell extract via immunoblot. As hypothesized, we observed a significant increase in lysine acetylation (Ac-lys) for all compounds (Fig. 5) . However, acetylation of histone 3 on lysine 9/14 (Ac-H3 K9/14) was only increased with treatment of emodin, gossypol, and quercetin dihydrate, but not luteolin; suggesting target and tissue specificity for these bioactive compounds. TSA, a potent and well-described pan-HDAC inhibitor [17] , was used as a positive control for analysis of lysine acetylation. Lastly, we noted no discernible toxicity or cell death of any bioactive HDAC inhibitor in H9c2 cells treated for 2 h.
Discussion
The findings in this report highlight a screening approach to determine bioactive compounds that inhibit HDAC activity. Using class-specific fluorescent substrates specific for Zndependent HDACs, we report that 18 out of 131 bioactive compounds inhibit HDAC activity in cardiac tissue. Moreover, the findings of this study define the individual HDAC(s) inhibited by these bioactive compounds. Consistent with HDAC inhibition, we further demonstrate an increase in lysine acetylation. Taken together, our data demonstrate that many dietary compounds can regulate the dynamic control of the epigenetic landscape and suggest that further exploration for the epigenetic impact of diet on gene regulation in chronic disease is needed.
Small molecule Zn-dependent HDAC inhibitors block cardiac remodeling and inflammation in response to myocardial infarction and hypertension [7] [8] [9] . Findings from this report highlight 18 dietary compounds that inhibit Zndependent HDAC activity in cardiac tissue (Table 1 ) and increase lysine acetylation in cardiac myoblasts (Fig. 5) . Based on these data, we would postulate a cardioprotective role for these compounds in the heart. Indeed, reports have highlighted a role for some of our identified compounds (e.g. epigallocatechin gallate (EGCG), luteolin, kaempferol) as cardioprotective [18] [19] [20] [21] . Luteolin for instance protects against ischemia/reperfusion-induced myocardial injury as well as angiotensin II-induced cardiac remodeling [20, 21] . In addition to this, some of our compounds have previously been implicated in the regulation of PTMs that include phosphorylation, acetylation, and methylation in other chronic disease states [4, 22, 23] . Quercetin is a prominent flavanol that has been studied for its anticarcinogenic and antihyperlipidemic actions [24] [25] [26] ; recent reports demonstrate biological actions of quercetin via inhibition of DNA methyl transferase 1 subsequently inhibiting methylation [26] or activation of NAD + -dependent HDACs (i.e. Sirtuins) [23, 27] . We further report that quercetin dihydrate acts as a pan-HDAC inhibitor ( Figs.  3 and 4 ; Tables 1 and 2 ). Collectively, our findings would argue that future research into the cardioprotective actions of these dietary compounds should examine their role as epigenetic modifiers of the nucleosomal landscape; with our data highlighting HDACs as targets of importance.
While our data supports a role for diet in the epigenetic regulation of heart health, our findings are translatable to other epigenetic diseases including cancer. Indeed, small molecule HDAC inhibitors Vorinostat and Romidepsin are currently approved by the US Food and Drug Administration (FDA) for the treatment of advanced cutaneous T-cell lymphoma [10, 22] , with more HDAC inhibitor monotherapy and combination therapy trials currently underway according to clinicaltrials.gov. Current nutrigenomic studies have demonstrated the importance of diet as chemopreventative and chemotherapeutic. More specifically, flavonoids have been identified as chemotherapeutic agents; these studies demonstrate that chemotherapeutic actions of flavonoids work in part by regulating histone modifications via alterations in acetylation and/or methylation [4, 22] . Compounds highlighted in this report including EGCG, kaempferol, quercetin, luteolin, and apigenin ( Fig. 1; Table 1 ) have been shown to regulate multiple posttranslational marks that include methylation and acetylation in order to block cancer proliferation and metastasis or promote cancer apoptosis [22] . With regards to our findings, EGCG, kaempferol, quercetin, and apigenin have previously been shown to regulate the Zn-dependent HDACs [1, 28, 29] . We report for the first time pan-HDAC inhibition by myricetin (Table 1) , which has previously been shown to act as an antiproliferative agent for the treatment of cancer [30, 31] . Thus, we would speculate that anticarcinogenic actions of myricetin are mediated in part through HDAC inhibition. In addition to myricetin, we report new evidence that flavonoids, baicalein, baicalin, dihydromyricetin, morin hydrate, and myricitrin ( Figs. 3 and 4 ; Tables 1 and 2) also inhibit Zn-dependent HDAC activity as well as which HDACs these compounds target (Table 2) . Combined, our findings uncover newly identified flavonoid HDAC inhibitors; thus, future examination of these dietary compounds in the epigenetic regulation of cancer prevention, cardioprotection, and other disease states would be of significant interest to the field of nutrigenomics.
While flavonoids comprise a large group of compounds examined in this study, we also highlight nonflavonoid compounds in the regulation of HDAC activity (Figs. 3 and  4 ; Tables 1 and 2 ). This is important, as flavonoids and nonflavonoids are present in the human diet. Similar to flavonoids, we report several previously undescribed nonflavonoid HDAC inhibitors, including berberine hydrochloride, gossypol, and palmatine (Table 1 and Fig. 1 ). Palmatine and gossypol have reported antiinflammatory and antioxidant actions via mechanisms involving reduced inflammatory gene expression and inhibition of inflammatory signaling cascades [32, 33] . Not surprisingly, HDAC inhibitors block inflammation in various disease models including cardiac disease [10] . Therefore, identification of these compounds as pan-HDAC inhibitors create future avenues of research to elucidate epigenetic mechanisms for these nonflavanoid dietary compounds in cardiac and other chronic disease states.
Given the role for Zn-dependent HDACs in a variety of pathophysiological processes that include cardiac disease, cancer, and inflammation, it is not surprising that there has been an increased emphasis on identifying and developing small molecule HDAC inhibitors in the pharmaceutical industry and in academic labs [10] . Structure-function studies using substrate peptides and inhibitors have revealed that HDAC inhibitors can be structurally grouped into at least four chemical classes: hydroxamic acids, short-chain fatty acids, benzamides, and cyclic peptides. Relative potencies and selectivity profiles differ between and within these classes [34] ; where hydroxamic acids produce potent (low nanomolar) pan-HDAC inhibitors, short-chain fatty acids weak (millimolar) HDAC inhibitors, while benzamides and cyclic peptides are generally selective for HDACs 1, 2, and 3. Additional studies have shown that HDAC inhibitors act as competitive inhibitors; meaning that they act within the HDAC catalytic site. Indeed, TSA and sodium butyrate have be shown to dock in the catalytic site of HDACs -1, -2, and -3 [35] . Of note, competitive inhibition of HDACs by TSA does not alter HDAC1 and -2 protein-protein interactions with repressor complex Sin3a or transcription factor Sp1 [35] . Thus, structure-function studies have allowed for the development of pan-, class-, and isoform-specific HDAC inhibitors. This is apparent in Fig. 2 , where HDAC inhibitor structure impacts HDAC class selectivity; TSA the first natural hydroxamate acts as a pan-HDAC inhibitor [36] , MGCD0103 selective against class I HDACs [37] , DPAH selective against class IIa HDACs [38] , and tubstatin A selective against HDAC6/class IIb HDACs [39] . Lastly, given the widespread implications for diet to regulate epigenetic gene expression, bioactive food compounds that inhibit HDAC activity have also become of immense interest in industry and Academia. Thus, it would be interesting to speculate further about dietary HDAC inhibitors; using molecular modeling tools investigators could delineate how the structure of our bioactive compounds (Fig. 3) as well as other food compounds regulate HDAC activity via docking at the catalytic site.
Concluding remarks
The emergence of nutrigenomics has highlighted the vast potential for bioactive compounds in the prevention and treatment of epigenetic diseases including heart disease and cancer [1,3]. As such, studies such as ours provide novel insights into bioactive compounds that regulate the epigenome, and in particular histone acetylation via inhibition of HDAC activity. Of note, our study did not examine the role for these bioactive compounds in the regulation of other epigenetic marks (e.g. methylation), nor did we examine the impact of these dietary compounds on other "writer" (e.g. HATs) or "eraser" (e.g. DNMT inhibitors) proteins. This is important as compounds such as EGCG have been shown to function as both HAT and HDAC inhibitors [22] , suggesting diverse epigenetic actions for dietary compounds in the regulation of disease. In addition, our study did not examine the impact of dietary HDAC inhibitors with regard to biological function, e.g. cardiac hypertrophy. However, this study provides the quintessential first step into unraveling newly identified natural food compounds as dietary HDAC inhibitors using screening-based technologies. As broad spectrum HDAC inhibitors are currently being studied for the treatment of various epigenetic diseases [17, 40] 
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